AstraZeneca licenses lung cancer drug Zegfrovy for $600m upfront
AstraZeneca licenses lung cancer drug Zegfrovy for $600m upfront
AstraZeneca licenses lung cancer drug Zegfrovy for $600m upfront
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.